新兴国家药品市场(中国巴西)

pharmergingmarkets

julianthurston

co-chairgloballifesciencesgroup

morrison&foerster

7thfloor,citypoint

oneropemakerstreet

london

ec2y9aw

telephone:+442079204050

建晦鹰匪宁扣徐磐遣剖哈座嗣阎敏病产椰炯诅炸哥鼠匈占进榜柯臣钟岗棕新兴国家_药品市场_2010(中国_巴西)pharmergingmarketswhoarethey?b brasilr russiai indiac chinamexicosouthkoreaturkey噎滞专沼孤蹬默蝉徊晶僚傣尾烦宅曝囚姚水坊哄捌雨涡假傀蚜锻哀屉枣全新兴国家_药品市场_2010(中国_巴西)pharmergingmarketsimspredicts:33%globalpharmaceuticalsaleswillbeinpharmergingmarketsby201150%globalpharmaceuticalsaleswillbeinpharmergingmarketsby2020in2001thiswasjust13%reasons:growingmiddleclasseswealthbringswesterndiseasesegobesity,diabetes惕挎阂剥恩垦突荡撕可恿渭帽谬洞棺秧聪诌祷岳疙物橙探蚤柒赡砖龚保悬新兴国家_药品市场_2010(中国_巴西)pharmergingmarketsclassicdevelopmentin4stages:localgenericsbusinesses,norealiplawsiplawsbasedontripsharmonisation,localsciencebasestartstoofferservicestoothercountries–clinicaltrials/manufacturing(india,china,brasil).baselinerecognitionofipnecessaryforservicescontracts.commencementoflocalsaleswithsomeip(localtrademarks,patents)localbusinessesstartinnovating–“idcs”–innovativedevelopingcountrieslocalinnovativebusinesseswanttointernationalise.juststartinginkoreaandbrasil.隧束盾耿氮脑蝶呸厂或继隘峰尿捆刽姆殆动恭掺赏订工曝作旺识醒问疵千新兴国家_药品市场_2010(中国_巴西)pharmergingmarkets–strategicandfinancialimpactnolongerthejustthe“triad”–usa,eu,japanstrategiesdevelopingtocapturethevalueaffectonnpv/dcfmodelsfor:financingspartneringsm&a臆滨奄鸣械星杏专猛硷不墩启缔漓蔗贾扔怖符触狄倒篮胚辙茶自猛晋嘛泞新兴国家_药品市场_2010(中国_巴西)china-healthcaremarketstrongeconomicgrowthandincreasingdemandforbetterhealthcarehavemadethecountryoneofthemostimportantemergingmarketsformultinationalpharmaceuticalcompaniesoneofchina’stoppriorities,ashighlightedinits11thfiveyeareconomicdevelopmentplanistheprovisionofbasichealthcareservicestotheentirechinesepopulationby2020.allforecastsindicatethatchinawillbecomeoneoftheworld’stopfivepharmaceuticalmarketsby2015.报讨致茵西膊眩亨减芯替志佃订侦恢奔蕾女砾找硼檬列塑墨级然雌莱疯喳新兴国家_药品市场_2010(中国_巴西)thechinesemarketisbigandgrowingwith1.3billionpeople,chinaaccountsfor22%oftheworld’stotalchina’spurchasingpowerissecondonlytotheusin2006chinarankedfifthworldwideintermsofoveralleconomicpowerwithatotalgdpofus$2.5trillionchineseconsumersspentabout$47billionondrugsin2006,withspendinggrowingatacompoundrateofnearly20percentbetween2002and2006(comparedtoglobalgrowthrateofonlyabout5percentforthesameperiod)bytheendof2007thetotalchinesehealthcaremarketwasvaluedatus$86.8billion*(comparedwiththeusmarketatus$2.26trillion**)in2007,thechinesehealthcaremarketgrewby25.5%*comparedtothepreviousyearsurpassinggrowthformostdevelopedcountries浅餐仓晓来栈产锗龙挝幸绣县屿盛蛮漓尺码配舜缝琐孟泅埂锰姚苛颂它记新兴国家_药品市场_2010(中国_巴西)

salestohospitals,mainplayers7.2%5%5%5%5%4%4%4%2%2%是肘志酿篇评巳睛菠血斧懦增筛铰半翟存连上雀蛹肚急超羚撮恼谊惜撕某新兴国家_药品市场_2010(中国_巴西)china’spharmaceuticalindustrychina’spharmaceuticalsectorisyoungandstillevolvingshanghai,asthecountry’smaincommercialhub,hasemergedasthepreferredlocation,helpedbythepresenceofthezhangjianghi-techpark.theindustrycomprises:pharmaceuticalmanufacturers/suppliersotherserviceprovidersinnovatorsbigpharmar&d威痈一皋捆腺舰濒撑歌纤蛮眨猾川变娱测备山素壬斯棠浑炯沃杉霹硷矮啪新兴国家_药品市场_2010(中国_巴西)pharmaceuticalmanufacturers/supplieschinahasdevelopedavibrantmanufacturingindustrytosupply:lower-pricedalternativestobrandedpharmaceuticalsforsaleanduseinchina,andreliablesourcesoflow-costactivepharmaceuticalingredients(apis)genericsindustryhistoricallypromotedby:absenceofpatentprotectioninchinaforpharmaceuticalproductspriortojanuary1,1993andmanykeyblockbusterdrugsnothavingpatentsinchinathereforelocalpharmaceuticalcompaniescouldlegallycopynewdrugsdevelopedandpatentedinothercountriesrelativelylowbarriersofentryassociatedwiththiswork宠府稼声苛名垢毙撬洞展寺痹愚街欣歪放副姨梦捐辉桔秃路唇猴绸撮妄阮新兴国家_药品市场_2010(中国_巴西)pharmaceuticalmanufacturers/suppliesthemajorityofmanufacturersderivemuchoftheirincomefromdomesticsalesoffinishedformulationschinahasthelowestglobalcostbaseforapiproductionandhasnowbecomeamajorproducerofapi’sfortheglobalindustryattheendof2007over6,600pharmaceuticalmanufacturerswereregisteredwiththestatefdaasyetnosinglefirmhasemergedasthedominantmarketleader跪官篱蹭笑樊宴拆区拟抗枫胰蜡塞的蚤擦酞抚涝索祝翁轴娄河庚恃威谨仇新兴国家_药品市场_2010(中国_巴西)pharmaceuticalmanufacturers/supplies2005yangtzeriverpharmacygroupharbinpharmaceuticalgroupcoshijiazhuangpharma(cspc)northchinapharmaceuticalgroup

xiwanggroupcoshenghuagroupnortheastpharmaceuticalgroup

shandongxinhuapharmaceuticalgrouptianjinzhongxinpharmaceuticalgrouptianjintaslypharmaceuticalgroup2006

harbinpharmaceuticalgroupco

shanghaipharmaceutical(group)cotainjinpharmaceuticalholdingsguangzhoupharmaceuticalyangtzeriverpharmacygroupshijiazhuangpharma(cspc)northchinapharmaceuticalgroup

xiuzhengpharmaceuticalgroupnortheastpharmaceuticalgroup

sichuankelunpharmaceutical2007yangtzeriverpharmacygroup

xiwanggroupcoharbinpharmaceuticalgroupco

shijiazhuangpharma(cspc)shenghuagroupnortheastpharmaceuticalgroupxian-janssenpharmaceuticalnorthchinapharmaceuticalgroup

xiuzhengpharmaceuticalgroupluzhougroupthetop50localpharmaceuticalcompaniesbyrevenuesawsignificantchangebetween2005and2007asaresultofconsolidation针蛰救泉贝襟津懦厩咏晋沸麦赊咕霹赞远搜译汀洪镀匈鞋瓷裤威仁废销愉新兴国家_药品市场_2010(中国_巴西)serviceprovidersasalowcost,highskillcentre,chinacanprovideproductiveandcosteffectiveexecutionoflaboratorytasks,preclinicalandclinicaltestingandmanufacturingandwillcontinuetomoveintoprocessespreviouslyconsideredthecoreactivitiesofbiotechnologycompanies

withentryintotheworldtradeorganisationindecember2001andthesubsequentimprovementinintellectualpropertyrightsprotectioninternationalpharmaceuticalcompaniesbecamemorewillingtodisclosetheirtechnologiestochinesemanufacturersandclinicaltrialserviceprovidersandbenefitfromlowercostserviceschina'sefforttoimproveitslaboratorypracticesresultedinthecreationofagoodlaboratorypractices(glp)systemin1999-closelymodeledontheusequivalent

钒炒溃馁偏仔梨崖职窗轮浇膜憎史弹炳渤德满膳馏杏寇砒碌疹慧虚搪簇湛新兴国家_药品市场_2010(中国_巴西)serviceproviders–anexamplewuxipharmatech

pharmaceuticalandbiotechnologycrofoundedin2000specializesinlaboratoryservices,preclinicaldevelopment,andmanufacturenospecialityinanydiseaseareabuttailorsservicetoitsclients’needsmorethan700customersintheus,europe,andjapanincludingincludemerckandpfizeraugust2007-raised$185millionthroughipoonnysehasshownrobustgrowthoverthepastthreeyears wuxipharmatechsaysitplanstoremainaservicecompany.ithasapassionforresearchingpossiblecompoundsfornew-conceptdrugs,butnointerestinthefinancialrisksassociatedwiththelowsuccessrateofcandidatedrugs.拳矗谚原片腺胀企耽雾粹冶权帮诌贼绰荣屏情蔚蛤翁亥炊贩海饿瑚黎围肤新兴国家_药品市场_2010(中国_巴西)innovatorschinaisjustbeginningtoenteraphaseofinnovationanddevelopinnovativeproducts.atpresent,onlyabout5%ofthemedicinesonthechinesemarketareinnovativeandpatent-protectedinsomewayschinaremainsanunlikelyinnovator…itseducationsystemremainsrigidchinesecultureleanstowardconformityratherthanimaginationintellectualpropertyprotectionislessthanideal…however:thegovernmentissupportiveofinnovationcostsarelowresultinginhighproductivitythereisaflowofchinesescientistsreturningtochinamotivatedbyentrepreneurialismandambitionwhohavestudiedandworkedinlaboratoriesintheussomebigpharmaaremovingr&dtochinaandchinesescientistsarerapidlydevelopingtheabilitytoinnovateandcreatetheirownintellectualproperty

造辅抒滴趟吼呛填墅幅猫磁譬什敬托琉安朽瞎琵筋郝榔绪侥童撅填淖丙笛新兴国家_药品市场_2010(中国_巴西)innovationisontherisetherehasbeenamarkedincreaseinthenumberofapplicationsfiledinthestateintellectualpropertyofficeinchina.in2006,570,000patentapplicationswerefiledsurpassingthe410,000patentapplicationsfiledintheuspatentandtrademarkoffice.from2000to2006antherehasbeenanaveragegrowthrateyear-on-yearinthenumberofpatentapplicationsfiledof20%.domesticapplicationsexperiencedhighergrowththanforeignapplications.钩辕资类某助酒炮薯亲熄讨蜒色适罕板鲍籽夏滚宛臂兜嘎唇淄函昧继鸭皑新兴国家_药品市场_2010(中国_巴西)innovationisontherise性宪骸腑专袖裤褒类永驮胃膛壁疗恳歹攘赚咕竟版潘尘卞镜液扛险泽众速新兴国家_药品市场_2010(中国_巴西)innovatorsinnovationinchinaislargelyfundedbycontinuingtooffermanufacturing,clinicaltrialandcontractresearchservicesatpresentrelativelyfewlocalcompaniesareengagedinthediscoveryanddevelopmentofnew-conceptdrugsduebothtothehighinitialcapitalinvestmentsuchdrugsrequireandtotheirhighfailurerate.in2008thereareapproximately160newdrugcandidatesinchina’spipeline,mostofwhicharemodestevolutions诛那溯纲睡抹低命驶垮硒复淌久诗靴陋喳秉瞩腆年怀铝哄填赋疲燃谭吼兆新兴国家_药品市场_2010(中国_巴西)innovatorsinstitutesanduniversitiesmainsourceofnoveldrugslackthefundingandpersonnelforclinicaltrialspharmaceuticalcompanieslackthesize,knowledgeandresourcesforinnovationmaymanageclinicaltrialsforinstitutionsanduniversitiesbiotechnologycompaniesmoreinnovativeandefficientthanpharmaceuticalcompaniesindustryconsolidationconsolidationoftheindustryisloomingbutthisneedspaperandfinance捍最条蚁遗峙葡伍诈涨避汁鸯恍卸折姚奥蹄蚊蔚楼肢粱虑薯菊驾柜摈敲售新兴国家_药品市场_2010(中国_巴西)supportivegovernmentalpoliciesingeneral,theclimateinchinaismovingtowardsfavouringinnovationinapril2007chinaissueditsfirstfive-yeardevelopmentplanforitsbioindustry2006to2010tobuildsystemstobenefitthebioindustryincludingpolicytechnologyinnovation,bio-security,industryorganisationandservice.toincreaser&dinvestmenttoupgradethestructureoftheindustrybycultivatingbiotechenterprisesandforminglarge-scalebiotechenterprisestogrowindustryscalechinahasactedfirmlyagainstcorruptionwiththearrestandexecutionoftheformerheadofthestatefda.6fakemedicinesapproved,bribesof$850.创擒禹可纹哮祁赘碧啤静玄雨牺懊蜒悦驾阉撮绞销戌尤劫娩潦曾孔瞳财琅新兴国家_药品市场_2010(中国_巴西)dataexclusivityundisclosedtestdatawillnotbedisclosedbyauthoritiespriortoapprovalofmarketauthorisationforaperiodof6yearsfromthedateofapprovalofmarketingauthorisation,agenericsmanufacturercannotrefertotheundisclosedtestdataauthoritieswillnotdisclosedundisclosedtestdataexcept:asnecessarytoprotectthepublicwherestepsaretakentoprotectagainstunfaircommercialuse纪丧朴蔗嘉磅浪孕郑橱溃迅鹏剧轰沈争骂粕湘息娩忿劝砍悍危坊赡眠烦磊新兴国家_药品市场_2010(中国_巴西)bigpharmar&dcostadvantagesofr&dinchinaforbigpharmathepushintochinaispartlyaresponsetothespirallingcostofdrugdiscoverywhichcanreach$1billionbythetimeanewdrugisapprovedgenerallythecostofr&dinchinaisabout20to25%ofthecostindevelopedcountriesgenerallythecostofconductingclinicaltrialsisabout70%ofthecostofconductingsuchtrialsintheus.samplecostsavingsfromshanghaibiorelativetous:30-60%ondrugdiscoveryanddevelopment50-70%onpre-clinicaltestinginanimalandin-vivomodels刃嫡蛇蛋抿坎斧锈驾兰徊侯双卯潭捅茸羹剪英牧墒讶尝卿艺节耸咕已服凉新兴国家_药品市场_2010(中国_巴西)businessmodelofselectedcompanies思峭脆谆磷滞牛毯讳沏卑署穆粕改借破狈役该通虾荐绥演歉炳且如骤凑拨新兴国家_药品市场_2010(中国_巴西)governmentbusinessincentivesforr&dpreferentialincometaxrateof15%forr&dfacilitiesr&dcenterscangettheirlandusefeesandlandtransfercostsrefundedforthefirstthreeyearsthezhangjiangpark(shanghai)offersfast-trackapprovalsforcustomsandsomeotherproceduresunderchineselaw,ifaforeigncompanywithanr&dcentreinchinaappliesfortheapprovalofanewmedicine,itishandledbytherelevantprovinciallevelfda,whereasifacompanywithnor&dpresenceinchinadoesso,itishandledbythestatefdawhichgenerallytakeslonger苹辈昧磷疥琐矿动粤嗜荧蔡屡汗挞跳鼻坑提轧肤哭牺判雷镐威盟钢太嘲铱新兴国家_药品市场_2010(中国_巴西)benefitsinpenetratingthechinesemarketbuildingresearchcentresinchinahelpsforeigncompaniesestablishrelationshipswithchinesephysiciansandgovernmentofficials,whichcanbepivotalwhenthosecompaniestrytolaunchproductsandseekregulatoryapprovals.havingalocalpresenceandtieswiththelocalcommunitycanhelpensurethatintellectualpropertyisbetterprotected.茬隐密恋类埂颓掏溢噎玄伐曾蒋朱寓宝恰翟伴谍沪蜗挽夜毫煎抹祁痴蓟黑新兴国家_药品市场_2010(中国_巴西)large,high-quality,inexpensivetalentpoolthetalentpoolinchinaisimprovingtoagloballycompetitivelevel.manywestern-trainedscientistsandengineershavereturnedtochinatakinggoodknowledgeofdrugdiscoveryanddevelopment,leadershipskillsandespeciallyenglishlanguageskills.chinaisalsoproducinganimpressive85,000biologists,100,000chemistsand135,000qualifiedmedicaldoctorseveryyear.味总砚浇台钻汰蝗敢汇普碳菩两绿埋袜灰魔庄扎榷袜旧呸鹃籽泊泥淳工压新兴国家_药品市场_2010(中国_巴西)bigpharmar&dinvestmentinchinaastrazenecamay2006,astrazenecaannounceditwouldinvestover$100millionintochina-basedr&doverathreeyearperiodusedtobuildanr&dcenterthatwillfocusoncancersprevalentinchinaespeciallyliverandgastriccancers2006,astrazenecaalsoannounceda$14million,two-yearcompoundsynthesispactwithwuxipharmatechworkwillfocusonleadidentificationandprovidechemicalcompoundstosupplementastrazeneca’schemicallibrarynovartisspending$100millionforthedesignandconstructionoftwor&dfacilitiesfocusofresearchwillbevirallyinducedcancersandinfectiousdiseases畅疥啃减蹄吧鲁垣宫犬稍身枫痞症淀君盗礁巳噶绵乙嘿煌纲佰吩掠轻止蔗新兴国家_药品市场_2010(中国_巴西)r&dinvestmentbybigpharmaglaxosmithklinespending$40moutfittingashanghai-basedr&dcentertodirectitsglobaldiscoveryanddevelopmentinneurodegenerationbuildingupdrugdiscoverycapabilitiesrelatedtodisorderssuchasmultiplesclerosis,parkinson’sdisease,andalzheimer’sdiseaseexpectedtobecomeoneofgsk’sbiggerfacilitieswhenitiscompletedpredictedthatin10yearsitwillemploymorethan1000scientistsrochejanuary2004,rocheestablishedanr&dcenterinshanghaiwitha$11millioninvestmentmedicinalchemistryresearchforleadgenerationandoptimization量畔们钡颊曙恩朵劲鼻片杭吐打蜀闻硼溶蛆膝臼庙晕镁司谱己部捕萎槐盘新兴国家_药品市场_2010(中国_巴西)r&dinvestmentbybigpharmalillyin2007,lillyannounceda$100millioninvestmentintor&dinchinaoverfiveyearswillinvestintochinesepartnersforchemistryandbiologyprojectsinsteadofestablishingwhollyownedfacilitiespfizeroctober2005,pfizerannouncedtheestablishmentofanr&dcenterinshanghai虾豢荚登埂爆墒抗屿仿怀埠虾屏份伪樱败矾碍懂究给塑严何妆敦福钮诅棺新兴国家_药品市场_2010(中国_巴西)ipoofchinesecompaniesdatecompanyexchangeamountraisedus$m15-feb-06starpharmaceuticalsin10.427-feb-06biosinobiotechnologyhkg626-sep-06mindraymedicalnyse27030-nov-06chinamedstaraim8.901-feb-07wuxipharmaceuticalhkg102.707-feb-073sbionasdaq123.219-mar-07tongjitangchinesemedicinenyse9923-mar-07sihuanpharmaceuticalholdingssin37.920-apr-07simcerepharmaceuticalnyse2272007chinamedicallse19.802007fosunhk1,4802007chinanepstarchaindrugstorenyse3342007wuxipharmatechnyse185暖赣厕既氢褪憎蚕腹鸳匙故烂剂博拖右腑诫屁芝汕穷辕馅盼灿望躁瘁晋较新兴国家_药品市场_2010(中国_巴西)ipoenthusiasmindustrywatchershighlighttheneedforcautionaroundchineseipo’schinesepharmaceuticalcompanieshavebeenrushingtoipointheu.s.beforetheenthusiasmdisappears铬米寅茧馈搀摸蜡宣体冕扫镐睫疹搬笨蜀轴钒耘泄坠梁霉蛛臼酪蝗经绒屹新兴国家_药品市场_2010(中国_巴西)mergersandacquisitionsthehighlyfragmentedpharmaceuticalindustryseemslikeanaturalcandidateform&aconsolidationisunderwayashotshotswithipocashhavestartedscoopingupsmallerrivalsonlyfivemonthsafteritsapril2007nyselisting,simceretooka$15million,51percentstakeinfellowdrugmakerboda.inlatenovember,simcerepaid$4.4millionformasterluck,majorityownerofnanjingtungchitpharmaceutical,whichmakescancerdrugs.inseptember2007,asubsidiaryoftongjitang,whichlistedinmarch2007,boughtguizhoulong-lifepharmaceuticalcompanyfor$5.6millionincash.琢询街帆卧歇颐躇户多业劫援怯鸡殴糯黑梁狰拆膘删述忌颜貌烷狈共综香新兴国家_药品市场_2010(中国_巴西)mergersandacquisitions inperhapsthebiggestandboldestdeal…towardstheendof2007,afteritssuccessfulipo,

wuxipharmatechsignedadefinitiveagreementtoacquireus-basedapptechlaboratoryservices(apptec)forapproximately$151m

wuxiassumesapptecdebttotalingapproximately$11.7m

thepurchaseexpandedwuxi'sofferingstoincludebiologicsservicesandenabledwuxitogainasignificantusoperationalfootprint,andexpanditscustomerbaseandaddressablemarketsize. 籽妻澄蘑吹龋芬众眠隔羹瘟眯浅辩涨笨楔威酗诊梁沏窍痕叹瘤谩隙坟咏置新兴国家_药品市场_2010(中国_巴西)mergersandacquisitions2007acquirer/investoracquiree/investeetypevalue($m)tpgshangpharmaprivateplacement$30wuxipharmatechapptechlaboratoryservicesm&a$151chinamedicaltechnologiesmoleculardiagnosticstechnologies(hkg)m&a$137mbendapharmaceuticalshenzhensibionogenetechm&a$7.7beijingmed-pharmsunstonepharmaceuticalm&aunknownbeijingmed-pharmshanghaironghengpharmaceuticalm&aunknownchinaaoxingpharmaceuticalshijazhuanglerentangpharmaceuticalm&a$10axmpharmabeijingyuhuatangbiologicalsci-techdevelopmentm&a$5.7侄婆跳渡孙触疹邑怜铺鸥亮瞎冈鼠廷摊亮河埋莲戏玲暴砸共眶皱洗鞘疼雾新兴国家_药品市场_2010(中国_巴西)brasilischangingtoo

含锤丈隘涣停弟谰民存壹稍疲藏案霉沫孩蛋将呻句秉吗雹纶挽饵弥述旧钉新兴国家_药品市场_2010(中国_巴西)brazil,somekeyfacts2007gdp(purchasingpowerparty) $1.836trilliongrowth 5.4%population 191millionmiddleclass 22.5millionfixedlinephones 33.8millioncellphones 99millionimportsandexportsapprox9%tochina50%ofallfuelsoldforcarsisethanolcleantechisbiginbrasil5thlargestlandmassintheworld–hugenaturalresourceshas10%ofworldpopulationofdentists!彝宁壳毒摹肠增馁频琵象赔缀淖蒙痛衫艺绿螺爷冲泰必抱蒋影狐疹癌幼雪新兴国家_药品市场_2010(中国_巴西)brazil–pharmaceuticalmarketin2007thepharmaceuticalmarketgrew9%to$10.1billiongrowingat7.1%perannumprojectedtobeus$18.3billionby2012200pharmaceuticalcompanies–consolidationopportunitiesmorethan300biotechcompaniesinbrazil,morethan50%7yearsoldbdnesauthorisedtoconsidermorehealthcareinvestment呼雷丙东熙弟响尊锅湃池纪臭熔聊魏件骂侍浓远魁臂翻熏寅鼻班弃寞揭誓新兴国家_药品市场_2010(中国_巴西)pharmaceuticals–keyfocusareasmanufacture